Search Results for “research” – Page 271 – media

Abbott supports Angle’s breast cancer liquid biopsy study

Healthcare firm Abbott will provide its PathVysion HER-2 DNA FISH probe kits for use in Angle's breast cancer liquid biopsy study.
- Source: invitrodiagnostics.medicaldevices-business-review
- 629
- February 13, 2018
Abbott breast cancer liquid biopsy Researches
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
- Source: finance.yahoo
- 748
- February 12, 2018
biopharmaceutical FDA major depressive disorder New Approvals
Best tech tools to communicate with patients? Time for doctors to ask

Cultivating a strong relationship with patients can translate into higher satisfaction scores but there is a widespread failure to communicate about the most appropriate way to reach consumers.
- Source: healthcareitnews
- 453
- February 12, 2018
healthcare Market Views
Major fertility breakthrough as human eggs grown in lab for first time

Human eggs have been fully grown in a laboratory for the first time in what has been hailed as a majorfertility breakthrough.
- Source: msn
- 494
- February 11, 2018
Human eggs majorfertility Researches
Scientists discover way to halt breast cancer spread

Scientists have uncovered a key mechanism that facilitates the spread of breast cancer cells, and thus a potential target for new therapeutic approaches in the fight against the disease.
- Source: pharmatimes
- 528
- February 11, 2018
breast cancer L-asparaginase Researches
Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC).
- Source: prnewswire
- 599
- February 11, 2018
Crohn’s disease IBD Janssen Johnson & Johnson ulcerative colitis
chemoWave app offers patients support during chemotherapy

Following a soft launch last year, the chemoWave disease companion app has now been fully released for chemotherapy patients interested in better managing their care, symptoms, and side effects.
- Source: MobiHealthNews
- 576
- February 11, 2018
Chemotherapy Company Insight digital health mHealth
SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for its oral formulation of TPOXX® (tecovirimat).
- Source: investor.siga
- 604
- February 9, 2018
DNA FDA New Approvals TPOXX
Another Day, Another Breakthrough Tag for GlaxoSmithKline’s Bexsero

GlaxoSmithKline’s meningitis B vaccine Bexsero is in a class all by itself when it comes to snagging the Breakthrough Therapy Designation from the U.S. Food and Drug Administration(FDA).
- Source: biospace
- 585
- February 9, 2018
Bexsero FDA GSK meningitis B vaccine
U.S. Food and Drug Administration Approves Gilead’s Biktarvy®

Gilead Sciences, Inc. on February 7 announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
- Source: Finchannel
- 787
- February 9, 2018
Biktarvy HIV-1 New Approvals STR

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.